Prospects of a novel vaccination strategy for human gamma-herpesviruses
- First Online:
- Cite this article as:
- Wu, TT., Blackman, M.A. & Sun, R. Immunol Res (2010) 48: 122. doi:10.1007/s12026-010-8172-z
- 209 Views
Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein–Barr virus (EBV or HHV-4) and Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.